You are here: Industry Insights > glucagon

News List

ViaCyte, Gore to Develop Technologies that Enhance Delivery of Therapies for Diabetes americanpharmaceuticalreview
March 05, 2021
ViaCyte and W. L. Gore & Associates announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte's portfolio of ...
US FDA approves first generic glucagon injection to treat severe hypoglycaemia expresspharma
December 29, 2020
The FDA granted this approval to Amphastar Pharmaceuticals of Rancho Cucamonga, California.
FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia drugs
September 12, 2019
Xeris Pharmaceuticals, Inc. a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations...
FDA Approves First Noninjection Glucagon Therapy drugs
July 26, 2019
The U.S. Food and Drug Administration has approved the first noninjection glucagon therapy for emergency treatment of severe hypoglycemia, the agency announced late yesterday.
FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia drugs
July 25, 2019
The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of...
Revealed structure of glucagon fibrils could improve drug formulation europeanpharmaceuticalreview
June 28, 2019
Researchers have discovered the formulation of glucagon fibrils, which could inform drug formulation for diabetic patients.
Ready-to-use glucagon for exercise-induced hypoglycaemia europeanpharmaceuticalreview
March 21, 2019
This study will evaluate the ready-to-use, room-temperature stable liquid glucagon as a pre-treatment to prevent exercise-induced hypoglycemia…
Xeris Raises $55M for Glucagon Rescue Pen biospace
March 12, 2018
Xeris Pharmaceuticals, Inc. secured $45 million in a Term Loan and Securities Agreement with Silicon Valley Bank and Oxford Finance, as well as closing a Series C financing with an additional $10 million.
Glucagon Receptor Structure Offers New Opportunities for Type 2 Diabetes Drug Discovery prnasia
January 05, 2018
Glucagon Receptor Structure Offers New Opportunities for Type 2 Diabetes Drug Discovery-PR Newswire Asia